Why Asthma Research Matters More Than Ever
Asthma is not one condition. It is a collection of different disease patterns, driven by different types of inflammation, and it responds differently from person to person. Around 3% to 10% of people with asthma have what specialists call severe disease, where standard inhalers barely keep symptoms in check. For decades, the fallback treatment for these patients has been oral steroids like prednisolone, drugs that calm inflammation but come with a punishing list of side effects: weight gain, bone thinning, diabetes risk, and mood changes.
The UK has been at the centre of a shift in thinking. Researchers at Oxford University Hospitals and Guy's and St Thomas' NHS Foundation Trust recently completed the ABRA trial, testing whether a single injection of benralizumab, a biologic drug that targets eosinophils (a type of white blood cell involved in allergic inflammation), could replace a five-day course of steroid tablets during an asthma attack. The results were striking enough that clinicians described it as the first meaningful change in acute asthma attack treatment in over fifty years. Patients who received the injection took longer to experience treatment failure and needed fewer follow-up hospital visits compared to those on steroids alone.
Meanwhile, King's College London led a landmark study across four European countries showing that 92% of patients on biologic therapies could safely reduce their inhaled steroid dose, and over 60% could stop using them altogether. These are not incremental improvements. They represent a genuine rethinking of what asthma control looks like.
The Biologic Revolution and Where Trials Fit In
Over the past decade, several biologic drugs have been approved for severe asthma. Benralizumab, mepolizumab, dupilumab, and tezepelumab each target different parts of the inflammatory cascade. In December 2025, the MHRA approved depemokimab (branded as Exdensur), the first ultra-long-acting biologic that requires only two injections per year. The SWIFT and ANCHOR phase III trials showed it could reduce exacerbation rates and hospitalisations, and the twice-yearly dosing schedule makes it a practical option for people who struggle with frequent clinic visits.
But approval is only half the story. Real-world evidence continues to accumulate through observational studies and post-marketing trials. The XALOC-2 study, for instance, has been tracking long-term remission rates in patients on benralizumab across multiple countries, including the UK, with researchers reporting that three-component clinical remission, defined as no exacerbations, no oral steroid use, and good symptom control over a twelve-month period, is achievable for a meaningful proportion of patients.
For anyone whose asthma remains uncontrolled despite high-dose inhalers, these trials are not abstract science. They are potential pathways to treatments that might not yet be available through routine NHS prescribing.
What Clinical Trials Actually Look Like in Practice
The phrase "clinical trial" can conjure images of sterile rooms and experimental risks. The reality tends to be more measured. Most asthma trials in the UK are run through NHS teaching hospitals, with research nurses and consultants who also work in routine respiratory care. Facilities like the NIHR Imperial Biomedical Research Centre in London, the Manchester Asthma and Allergy Study, and the Leicester respiratory research unit are embedded within the NHS, not separate from it.
A typical trial visit might involve lung function tests (spirometry), blood and sputum samples, and a review of your symptom diary. Some trials ask participants to use remote monitoring devices at home, a development accelerated by the pandemic era. The Imperial College team is currently validating remote lung-function monitoring tools for use in interventional trials, which could eventually reduce the burden of hospital visits.
The table below outlines the broad categories of asthma trials currently recruiting or active across the UK.
| Trial Type | Example Focus | Typical Duration | Suitable For | Key Consideration |
|---|
| Biologic therapy trials | Testing new or existing biologics for severe asthma | 6 months to 2 years | Adults and adolescents with eosinophilic or type 2 inflammation | May require regular blood monitoring |
| Acute exacerbation studies | Treating attacks with alternatives to steroids | Short-term (90 days follow-up) | People with history of eosinophilic attacks | Requires attending hospital at time of exacerbation |
| Medication reduction trials | Seeing if biologics allow lower steroid doses | 12 to 18 months | Patients already on biologic therapy | Close supervision from research team |
| Paediatric asthma trials | Comparing treatments specifically in children | Varies | Children with severe or difficult-to-control asthma | Extra safeguards and parental consent required |
| Observational studies | Tracking real-world outcomes without changing treatment | Often 2 years or more | Broad patient populations | No change to current medication |
How to Find a Trial That Fits
The NHS "Be Part of Research" website is the most straightforward starting point. It aggregates trials from multiple UK registries and lets you search by condition, location, and eligibility. You can contact research teams directly through the site rather than waiting for a GP referral.
For asthma specifically, there is REACH (Register for Asthma Research), run by the Asthma UK Centre for Applied Research. REACH securely stores your contact details and only notifies you when a study matches your profile. It is a low-effort way to stay informed without committing to anything upfront. The charity Asthma + Lung UK also maintains information about ongoing research and can point you toward relevant opportunities.
If you are under the care of a specialist asthma clinic, ask your consultant. Many severe asthma centres in cities like London, Manchester, Birmingham, Leicester, Edinburgh, and Glasgow are actively recruiting for trials, and being an existing patient at one of these centres can be a practical advantage. The Manchester Asthma and Allergy Study, for example, has been following participants for over twenty-five years and is still recruiting for follow-up studies, demonstrating how long-term research relationships can benefit both patients and science.
A word on eligibility: each trial has specific criteria. Some look for people with blood eosinophil counts above a certain threshold. Others require a history of two or more exacerbations in the past year despite using high-dose inhalers. Age ranges vary, and some trials exclude people with certain other conditions. Being told you do not qualify for one study does not mean you will not qualify for another. The criteria are designed to answer specific research questions, not to judge the severity of your asthma.
What Happens After You Express Interest
Once you contact a research team, you will typically have an initial conversation where the study is explained in plain English. You will receive a patient information sheet covering the purpose of the trial, what is involved, potential risks, and your right to withdraw at any time. This is a legal requirement under UK research ethics regulations, and you should take the time to read it carefully.
If you decide to proceed, you will sign a consent form and attend a screening visit where the team checks your eligibility through blood tests, lung function measurements, and a review of your medical history. Some people are not eligible at this stage, and that is normal. The screening process exists to protect participants as much as to ensure the quality of the research data.
Participants in UK clinical trials are not charged for the treatments being tested, and any travel expenses incurred for study visits are typically reimbursed. The research is funded by organisations like the National Institute for Health and Care Research (NIHR), medical charities, and pharmaceutical companies, but the care itself is delivered through the NHS.
Regional Research Hubs Worth Knowing
London has the highest concentration of asthma research activity in the UK. Imperial College Healthcare NHS Trust, based at St Mary's Hospital in Paddington, runs trials on everything from the common cold in asthma patients to novel biologic therapies. Guy's and St Thomas' has been a key site for the ABRA trial and other exacerbation studies. The Royal Brompton Hospital, now part of Guy's and St Thomas', has a long-standing reputation in respiratory medicine.
Outside London, the University of Leicester has a dedicated respiratory biomedical research unit, and the Manchester Asthma and Allergy Study continues to generate insights into how asthma develops from childhood into adulthood. In Scotland, the Royal Hospital for Children in Glasgow and the Royal Hospital for Sick Children in Edinburgh have both been involved in paediatric asthma trials, including the TREAT study comparing mepolizumab and omalizumab in children with severe disease.
The NIHR Clinical Research Network coordinates much of this activity across England, and the equivalent bodies in Scotland, Wales, and Northern Ireland perform similar roles. What this means for patients is that participating in a trial does not necessarily require travelling to London. Many studies recruit from multiple sites across the country.
Making Sense of the Risks
Every clinical trial carries some uncertainty. The treatments being tested may not work for everyone, and side effects, while carefully monitored, are possible. In the ABRA trial, for instance, benralizumab was generally well tolerated, but participants were monitored for hypersensitivity reactions and other adverse events. The research team's job is to explain these risks clearly before you consent.
The counterbalance is that trial participants receive close monitoring that often exceeds routine NHS care. Lung function tests, blood work, and consultant reviews happen more frequently than they would during standard clinic visits. For people with severe asthma, this level of attention can be reassuring in itself.
It is also worth remembering that the UK has a robust system of research ethics committees that must approve every trial before it begins. The Health Research Authority oversees this process, and no study can recruit participants without a favourable ethical opinion. These are not small safeguards.
The question of whether to join a clinical trial is personal. Some people are motivated by the possibility of accessing a treatment that is not yet widely available. Others want to contribute to knowledge that might help people with asthma in the future. Neither motivation is more valid than the other. What matters is that you have enough information to make the decision that feels right for you, and that you know where to start looking.
研究の知恵